PMS-PROCHLORPERAZINE SUPPOSITOIRES 10MG SUPPOSITORY Канада - английски - Health Canada

pms-prochlorperazine suppositoires 10mg suppository

pharmascience inc - prochlorperazine - suppository - 10mg - prochlorperazine 10mg - phenothiazines

PROCHLORPERAZINE- prochlorperazine suppository САЩ - английски - NLM (National Library of Medicine)

prochlorperazine- prochlorperazine suppository

nucare pharmaceuticals,inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine suppositories, usp 25 mg are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

PROCHLORPERAZINE MALEATE tablet САЩ - английски - NLM (National Library of Medicine)

prochlorperazine maleate tablet

glenmark pharmaceuticals inc., usa - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazinewill be useful in patients with other non-psychotic conditions in wh

PROCHLORPERAZINE tablet САЩ - английски - NLM (National Library of Medicine)

prochlorperazine tablet

pharmpak, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that pr

PROCHLORPERAZINE tablet САЩ - английски - NLM (National Library of Medicine)

prochlorperazine tablet

pharmpak, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that pr

COMPAZINE- prochlorperazine suppository САЩ - английски - NLM (National Library of Medicine)

compazine- prochlorperazine suppository

pbm pharmaceuticals, inc - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 25 mg - prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

COMPRO- prochlorperazine suppository САЩ - английски - NLM (National Library of Medicine)

compro- prochlorperazine suppository

pd-rx pharmaceuticals, inc. - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 25 mg - prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

COMPRO- prochlorperazine suppository САЩ - английски - NLM (National Library of Medicine)

compro- prochlorperazine suppository

padagis us llc - prochlorperazine (unii: yhp6ylt61t) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 25 mg - prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.). do not use in pediatric surgery. do not use in children under 2 years of age or under 20 lbs. do not use in children for conditions for which dosage has not been established.

PROCHLORPERAZINE MALEATE tablet САЩ - английски - NLM (National Library of Medicine)

prochlorperazine maleate tablet

redpharm drug, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with othe

PROCHLORPERAZINE MALEATE tablet САЩ - английски - NLM (National Library of Medicine)

prochlorperazine maleate tablet

redpharm drug, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with othe